FluoGuide provides update on 2026 outlook and progress
The company reports positive results on milestones with minor timing adjustments, outlining progress in brain and head and neck cancer trials.
See the latest news and media coverage for FluoGuide. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing precision cancer surgery drugs
fluoguide.comLast updated
In short: FluoGuide received FDA Fast Track status for FG001, reported positive Phase 2 oral cancer results, and advanced its US clinical program.
The company reports positive results on milestones with minor timing adjustments, outlining progress in brain and head and neck cancer trials.
Optimal dose 0.30 mg/kg identified in 15 patients; FG001 well tolerated and detected by all near-infrared imaging systems.
The report details FDA IND authorization and Fast Track Designation for FG001, and progress in head and neck cancer program.
Dr. Jane Skjøth-Rasmussen shared data at Brain Tumor Symposium 2026 in Copenhagen, highlighting FG001's potential to improve tumor delineation in meningioma and low-grade glioma surgery.
FluoGuide reported progress on its imaging-based cancer diagnostics platform for the first half of 2026. Key milestones included FDA approval for the first US study site for...
FluoGuide A/S has published its financial results for the second quarter and the first half year ended June 30, 2026. For the second quarter, the...
COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) , a clinical-stage biotech company focused on precision cancer...
COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology...
Track FluoGuide and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.